4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,870.00
arrow_upward
+1.04%(+40.00) 1D
ኖቬም 13, 10:43:31 ጥዋት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,860
High
JP¥3,880
Low
JP¥3,830
Mkt. cap
180.12 ቢ
Avg. vol.
85.82 ሺ
Volume
27.00 ሺ
Dividend
3.23%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.34
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,860
High
JP¥3,880
Low
JP¥3,830
Mkt. cap
180.12 ቢ
Avg. vol.
85.82 ሺ
Volume
27.00 ሺ
Dividend
3.23%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.34
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
Eurasia Business News
·
ከ2 ሰዓቶች በፊት
Stock Market Today, November 12, 2026: Dow, S&P 500 and Nasdaq Fall After Jensen Huang Resigns
Investing.com
·
ከ4 ሰዓቶች በፊት
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.36%
The Motley Fool
·
ከ7 ሰዓቶች በፊት
The S&P 500 Is Hiding a Sneaky Risk. Here's How Investors Can Prepare for Potential Volatility.
Traders Union
·
ከ4 ሰዓቶች በፊት
Jake Wujastyk: S&P 500 and ES_F trade within last Thursday's range for a full week
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp